姚记科技(002605) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥981,142,310.13, representing an increase of 83.59% compared to ¥534,420,305.80 in the same period last year[9]. - The net profit attributable to shareholders of the listed company decreased by 70.07% to ¥198,589,062.29 from ¥663,428,466.20 year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 26.49% to ¥182,763,225.96 compared to ¥144,493,827.59 in the previous year[9]. - The basic earnings per share decreased by 70.17% to ¥0.4959 from ¥1.6626 in the same period last year[9]. - The diluted earnings per share decreased by 72.08% to ¥0.4564 from ¥1.6344 year-on-year[9]. - The weighted average return on equity was 8.99%, down 27.35% from 36.34% in the previous year[9]. - The company reported a total operating cost of ¥771,185,326.04, up from ¥347,101,634.07, which is an increase of about 122%[70]. - The profit margin decreased significantly, with the net profit margin for the current period at approximately 76.7%, down from 97.4% in the previous period[70]. - The total comprehensive income for the current period was ¥200,784,727.70, down from ¥674,467,099.79, reflecting a decrease of about 70%[73]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 35.01% to ¥184,698,817.90 from ¥136,801,283.27 in the same period last year[9]. - As of March 31, 2021, the company's cash and cash equivalents amounted to RMB 803.86 million, an increase from RMB 659.09 million at the end of 2020, representing a growth of approximately 21.9%[48]. - Cash inflow from operating activities totaled CNY 1,081,324,421.18, up from CNY 611,099,275.25 in the prior period, representing an increase of approximately 77.0%[81]. - Cash inflow from sales of goods and services reached CNY 1,001,463,810.31, compared to CNY 546,239,817.75 in the prior period[81]. - The ending balance of cash and cash equivalents was CNY 691,924,252.76, an increase from CNY 538,543,110.79 in the previous period[87]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,053,549,693.19, an increase of 4.30% from ¥3,886,358,589.27 at the end of the previous year[9]. - The total liabilities decreased to CNY 1,368,152,359.18 from CNY 1,399,479,577.52, reflecting a reduction of approximately 2.2%[64]. - The total equity attributable to shareholders increased to CNY 2,493,323,754.93 from CNY 2,513,201,397.26, showing a slight decrease of about 0.8%[64]. - The company's total equity as of January 1, 2021, was CNY 2,114,708,039.49, up from CNY 2,114,065,191.18, showing an increase of CNY 642,848.31[96]. - Total liabilities rose to CNY 1,814,090,970.27, compared to CNY 1,772,293,398.09 at the end of 2020, indicating an increase of CNY 41,797,572.18[96]. Investments and Expenditures - The company reported a 41.12% increase in capital reserves to CNY 30,625,901.73 due to the recognition of option expenses[24]. - The company experienced a 96.13% decline in investment income to CNY 19,474,373.07 due to changes in accounting treatment for its stake in Shanghai Cell Therapy Group[27]. - The company has invested RMB 1.85 million in entrusted financial management products, with an outstanding balance of RMB 400,000[39]. - The company plans to transfer a 2% equity stake in Shanghai Cell Therapy Group Co., Ltd. for a total price of RMB 110 million, reducing its ownership from 14.2119% to 12.2119%[32]. Shareholder Actions - The company plans to repurchase shares with a total amount between CNY 30 million and CNY 60 million, with a maximum price of CNY 35 per share[31]. - The company has repurchased a total of 1,146,897 shares, accounting for about 0.29% of the total share capital, with a total transaction amount of RMB 30.00 million[32]. - The company plans to use the repurchased shares for employee stock ownership plans or equity incentive plans[32]. Research and Development - Research and development expenses grew by 45.23% to CNY 41,506,690.47 due to an increase in R&D personnel[27]. - Research and development expenses increased to ¥41,506,690.47 from ¥28,579,664.76, reflecting a growth of approximately 45%[70]. Government Support - The company received government subsidies amounting to ¥11,437,121.15 during the reporting period[9].